

**LARS KLARESKOG PUBLICATIONS 2017****Peer-reviewed articles**

1. Alfredsson L, Hedstrom AK, Akerstedt T, Klareskog L. Relationship between Shift Work and the Onset of Rheumatoid Arthritis; Results from a Swedish Case-Control Study. *Arthritis & Rheumatology*. 2017;69.
2. Alfredsson L, Hedstrom AK, Bengtsson C, Klareskog L. Smoking and Rheumatoid Arthritis Susceptibility; Quantification of the Impact of Cumulative Dose, Frequency and Duration of Smoking, and Smoking Cessation. *Arthritis & Rheumatology*. 2017;69.
3. Alfredsson L, Hedstrom AK, Klareskog L. Exposure to Passive Smoking and RA Risk; Results from a Swedish Case-Control Study. *Arthritis & Rheumatology*. 2017;69.
4. Aulin C, Lundback P, Palmblad K, Klareskog L, Harris HE. An in vivo cross-linkable hyaluronan gel with inherent anti-inflammatory properties reduces OA cartilage destruction in female mice subjected to cruciate ligament transection. *Osteoarthritis and Cartilage*. 2017;25(1):157-65.
5. Aulin C, Palmblad K, Klareskog L, Harris HE. Cartilage protective effects of HMGB1-neutralizing therapy in experimental osteoarthritis. *Scandinavian Journal of Immunology*. 2017;86(4):336-.
6. Aulin C, Palmblad K, Klareskog L, Harris HE. CARTILAGE-SAVING EFFECTS OF LOCAL HMGB1-NEUTRALIZING THERAPY IN EXPERIMENTAL OSTEOARTHRITIS. *Osteoarthritis and Cartilage*. 2017;25:S435-S.
7. Brauner S, Folkersen L, Kvarnstrom M, Meisgen S, Petersen S, Franzen-Malmros M, et al. H1N1 vaccination in Sjogren's syndrome triggers polyclonal B cell activation and promotes autoantibody production. *Annals of the Rheumatic Diseases*. 2017;76(10):1755-63.
8. Brink M, Hansson M, Mathson-Alm L, Cornillet M, Ronnelid J, Skriner K, et al. ACPA AGAINST DIFFERENT CITRULLINATED PEPTIDES IDENTIFY SPECIFIC PHENOTYPES OF RHEUMATOID ARTHRITIS. *Annals of the Rheumatic Diseases*. 2017;76:792-.
9. Catrina AI, Svensson CI, Malmstrom V, Schett G, Klareskog L. Mechanisms leading from systemic autoimmunity to joint-specific disease in rheumatoid arthritis. *Nature Reviews Rheumatology*. 2017;13(2):79-86.
10. Curtis J, Emery P, Burmester G, Arora V, Alam J, Muram D, et al. EFFECTS OF SMOKING ON BARICITINIB EFFICACY IN PATIENTS WITH RHEUMATOID ARTHRITIS: POOLED ANALYSIS FROM TWO PHASE 3 CLINICAL TRIALS. *Annals of the Rheumatic Diseases*. 2017;76:244-.

11. Gerlag D, Safy M, Maijer K, Ramwadhoebe T, Tas S, de Vries N, et al. THE EFFECTS OF B CELL DIRECTED THERAPY ON DISEASE RELEVANT BIOMARKERS IN SUBJECTS AT RISK OF RHEUMATOID ARTHRITIS. *Annals of the Rheumatic Diseases*. 2017;76:781-.
12. Gronwall C, Amara K, Hardt U, Krishnamurthy A, Steen J, Engstrom M, et al. Autoreactivity to malondialdehyde-modifications in rheumatoid arthritis is linked to disease activity and synovial pathogenesis. *Journal of Autoimmunity*. 2017;84:29-45.
13. Guerreiro-Cacais AO, Norin U, Gyllenberg A, Berglund R, Beyeen AD, Petit-Teixeira E, et al. VAV1 regulates experimental autoimmune arthritis and is associated with anti-CCP negative rheumatoid arthritis. *Genes and Immunity*. 2017;18(1):48-56.
14. Hedstrom AK, Klareskog L, Alfredsson L. EXPOSURE TO PASSIVE SMOKING AND RA RISK; RESULTS FROM THE SWEDISH EIRA STUDY. *Annals of the Rheumatic Diseases*. 2017;76:1511-2.
15. Ilar A, Gustavsson P, Wiebert P, Bengtsson C, Klareskog L, Alfredsson L. Occupational Exposure to Asbestos and Risk of Rheumatoid Arthritis. *Arthritis & Rheumatology*. 2017;69.
16. Ilar A, Gustavsson P, Wiebert P, Bengtsson C, Klareskog L, Alfredsson L. OCCUPATIONAL EXPOSURE TO ASBESTOS AND RISK OF RHEUMATOID ARTHRITIS. *Annals of the Rheumatic Diseases*. 2017;76:248-.
17. Lancelot M, Grimaud O, Saevarsdottir S, Askling J, Klareskog L, Alfredsson L, et al. Diet Change and Omega-3 Supplementation in the First Three Years Following a Diagnosis with Rheumatoid Arthritis in Sweden. *Arthritis & Rheumatology*. 2017;69.
18. Lindqvist J, Westerlind H, Klareskog L, Alfredsson L, Lampa J. SUBGROUPING OF EARLY RA-PATIENTS IDENTIFIED CLUSTER OF PATIENTS WITH HIGH LEVELS OF PAIN, FATIGUE AND PSYCHOSOCIAL DISTRESS 3 YEARS AFTER DIAGNOSIS. *Annals of the Rheumatic Diseases*. 2017;76:1038-.
19. Lloyd KA, Sahlstrom P, Steen J, Titcombe PJ, Zhou D, Lundqvist C, et al. ovel Interaction between Anti-Citrulline Monoclonal Antibodies and Apoptotic Cells Is Mediated through Citrullinated Nuclear Antigens. *Arthritis & Rheumatology*. 2017;69.
20. Lloyd KA, Steen J, Titcombe PJ, Amara K, Zhou D, Israelsson L, et al. Monoclonal ACPA-IgG Feature Extensive Fab Glycosylation. *Arthritis & Rheumatology*. 2017;69.
21. Lloyd KA, Steen J, Titcombe PJ, Mueller DL, Klareskog L, Malmstrom V, et al. VARIABLE DOMAIN N-LINKED GLYCOSYLATION IS A KEY FEATURE OF MONOCLONAL ACPA-IGG. *Annals of the Rheumatic Diseases*. 2017;76:A82-A3.
22. Lundstrom SL, Hensvold AH, Rutishauser D, Klareskog L, Ytterberg AJ, Zubarev RA, et al. IgG Fc galactosylation predicts response to methotrexate in early rheumatoid arthritis. *Arthritis Research & Therapy*. 2017;19.

23. Malmstrom V, Catrina AI, Klareskog L. The immunopathogenesis of seropositive rheumatoid arthritis: from triggering to targeting. *Nature Reviews Immunology*. 2017;17(1):60-75.
24. Manivel VA, Mullazehi M, Padyukov L, Westerlind H, Klareskog L, Alfredsson L, et al. Anticollagen type II antibodies are associated with an acute onset rheumatoid arthritis phenotype and prognosticate lower degree of inflammation during 5 years follow-up. *Annals of the Rheumatic Diseases*. 2017;76(9):1529-36.
25. Manivel VA, Mullazehi M, Padyukov L, Westerlind H, Klareskog L, Alfredsson L, et al. ANTI-COLLAGEN TYPE II ANTIBODIES ARE ASSOCIATED WITH AN ACUTE ONSET RHEUMATOID ARTHRITIS PHENOTYPE AND PROGNOSTICATE LOWER DEGREE OF INFLAMMATION. *Annals of the Rheumatic Diseases*. 2017;76:228-.
26. Meng WD, Zhu ZH, Jiang X, Too CL, Uebe S, Jagodic M, et al. DNA methylation mediates genotype and smoking interaction in the development of anti-citrullinated peptide antibody-positive rheumatoid arthritis. *Arthritis Research & Therapy*. 2017;19.
27. Orellana C, Saevarsdottir S, Klareskog L, Karlson EW, Alfredsson L, Bengtsson C. Oral contraceptives, breastfeeding and the risk of developing rheumatoid arthritis: results from the Swedish EIRA study. *Annals of the Rheumatic Diseases*. 2017;76(11):1845-52.
28. Shchetynsky K, Diaz-Gallo LM, Folkersen L, Hensvold AH, Catrina AI, Berg L, et al. Discovery of new candidate genes for rheumatoid arthritis through integration of genetic association data with expression pathway analysis. *Arthritis Research & Therapy*. 2017;19.
29. Steen J, Forsstrom B, Israelsson L, Krishnamurthy A, Hansson M, Sahlstrom P, et al. MONOCLONAL ACPA ANTIBODIES RECOGNISING A COMMON CITRULLINE MOTIF ARE MAINLY DEPENDENT ON LIGHT CHAIN HYPERMUTATIONS FOR ANTIGEN RECOGNITION. *Annals of the Rheumatic Diseases*. 2017;76:A85-A.
30. Titcombe PJ, Wigerblad G, Sippl N, Zhang N, Shmagel AK, Sahlstrom P, et al. Citrulline-Polyspecific B Cell Antigen Receptors Arising from Somatic Hypermutation within Clades Demonstrate Pathogenicity in Rheumatoid Arthritis. *Arthritis & Rheumatology*. 2017;69.
31. Too CL, Murad S, Hansson M, Alm LM, Dhaliwal JS, Holmdahl R, et al. Differences in the Spectrum of Anti-Citrullinated Protein Antibody Fine Specificities Between Malaysian and Swedish Patients With Rheumatoid Arthritis: Implications for Disease Pathogenesis. *Arthritis & Rheumatology*. 2017;69(1):58-69.
32. Too CL, Tan LK, Aain AFN, Salsabil S, Heselynn H, Wahinuddin S, et al. FAMILIAL RISKS OF RHEUMATOID ARTHRITIS: EVIDENCE FROM THE MALAYSIAN EPIDEMIOLOGICAL INVESTIGATION OF RHEUMATOID ARTHRITIS CASE-CONTROL STUDY. *Annals of the Rheumatic Diseases*. 2017;76:1512-.

33. Westerlind H, Schelin ME, Altawil R, Klareskog L, Alfredsson L, Lampa J. PREDICTORS AND PERSISTENCE OF UNACCEPTABLE PAIN DURING THE FIRST YEAR OF RHEUMATOID ARTHRITIS IN SWEDEN. *Annals of the Rheumatic Diseases*. 2017;76:1037-.
34. Westra HJ, Martinez-Bonet M, Onengut S, Lee A, Luo Y, Teslovich N, et al. Fine-Mapping Identifies Causal Variants for RA and T1D in DNASE1L3, Sirpg, MEG3, TNFAIP3 and CD28/CTLA4 Loc. *Arthritis & Rheumatology*. 2017;69.
35. Zeng PL, Alfredsson L, Klareskog L, Mullazehi M, Saevarsdottir S, Bengtsson C, et al. Occupational Physical Workload and Development of Anti-Collagen Type II Antibodies in Rheumatoid Arthritis Patients. *Arthritis & Rheumatology*. 2017;69.